Subscribe
The Broad-Spectrum Snakebite Antidote IPT and small-business partner, Ophirex Inc, accelerated the technical and programmatic maturity of the critical life-saving drug, varespladib, including two pivotal clinical trials in 4 years. The team mitigated manufacturing and clinical risks through early FDA engagement and capitalized on opportunities to accelerate schedule, utilizing SBIR contracting mechanisms; financial and acquisition planning; and stakeholder engagement. The team’s efforts will result in FDA-approval and fielding nearly 3 years ahead of schedule, providing an important capability for Warfighters deployed in far-forward, austere conditions where snakebites are a significant threat to life and limb.
This version of the video has captions embedded.
| Date Taken: | 08.14.2023 |
| Date Posted: | 08.14.2023 14:30 |
| Category: | Video Productions |
| Video ID: | 893747 |
| VIRIN: | 230814-O-XH734-5608 |
| Filename: | DOD_109827019 |
| Length: | 00:03:47 |
| Location: | US |
| Downloads: | 3 |
| High-Res. Downloads: | 3 |
This work, MHSRS Award Winner: Broad-Spectrum Snakebite Antidote IPT (captioned), by Sara Barger, identified by DVIDS, must comply with the restrictions shown on https://www.dvidshub.net/about/copyright.
